Regeneron (REGN) Misses Q1 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
Regeneron (REGN) misses earnings, revenue expectations
May 2, 2024 7:05 AM EDTRegeneron (NASDAQ: REGN) experienced a slight decline in its stock price, falling 1.82% after reporting first-quarter earnings and revenue that fell short of Wall Street expectations. The biotechnology company announced an adjusted EPS of $9.55, which was below the analyst estimate of $10.19. Revenue for the quarter was $3.15 billion, also missing the consensus estimate of $3.22 billion.
Despite the overall revenue decrease of 1% from the same quarter last year, the company highlighted a 7% increase when excluding sales from Ronapreve, a COVID-19 treatment. Notably,... More
